What is Core Biogenesis?
Core Biogenesis operates at the intersection of biotechnology and sustainable manufacturing, specializing in the development of advanced solutions for regenerative medicine and longevity skincare. The company utilizes a proprietary platform that transforms plants into efficient biofactories, enabling the production of high-value recombinant proteins with enhanced stability. By targeting these proteins to plant oleosomes, Core Biogenesis addresses critical bottlenecks in traditional bioproduction methods, offering a more sustainable and scalable alternative for the life sciences sector. This innovative methodology positions the company as a key player in the transition toward greener, more efficient manufacturing processes in the health and wellness markets.
How much funding has Core Biogenesis raised?
Core Biogenesis has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2022): $10.5M with participation from Thia Ventures, Blue Horizon Ventures, and XAnge
Key Investors in Core Biogenesis
Thia Ventures
Thia Ventures is a fund management company that focuses on investments at the intersection of food, biotechnology, and health, supporting innovative ventures that drive growth and development.
Blue Horizon Ventures
Blue Horizon Ventures is a food technology-focused venture capital fund dedicated to supporting a more sustainable food system through innovation, technology, and entrepreneurship.
XAnge
XAnge is a European early-stage venture capital firm with over 20 years of experience, dedicated to empowering visionary founders from Seed to Series B with capital and expertise.
What's next for Core Biogenesis?
Looking ahead, the infusion of capital will likely be directed toward scaling the company's bioproduction infrastructure and expanding its commercial partnerships. As Core Biogenesis transitions into its next phase of growth, the focus will remain on optimizing its plant-based platform to meet the increasing demand for high-purity proteins in clinical and cosmetic applications. Strategic priorities include enhancing the stability of its protein portfolio and potentially exploring new therapeutic applications within the regenerative medicine space. With the support of its current investor base, the company is well-equipped to navigate the complexities of the biotech landscape and drive long-term value through continued innovation and operational excellence.
See full Core Biogenesis company page
